Gainers

• Axe Compute (NASDAQ:AGPU) stock rose 148.8% to $12.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $16.5 million.
• Kyverna Therapeutics (NASDAQ:KYTX) stock moved upwards by 15.46% to $11.21. The company's market cap stands at $587.0 million.
• Alpha Compute (NASDAQ:ALP) stock moved upwards by 12.71% to $0.32. The market value of their outstanding shares is at $6.5 million.
• Inhibrx Biosciences (NASDAQ:INBX) stock rose 11.54% to $93.79. The market value of their outstanding shares is at $1.2 billion.
• Teleflex (NYSE:TFX) stock moved upwards by 10.62% to $138.0. The market value of their outstanding shares is at $5.5 billion.
• Spruce Biosciences (NASDAQ:SPRB) stock rose 10.13% to $56.93. The market value of their outstanding shares is at $70.9 million.

Losers

• Psyence Biomedical (NASDAQ:PBM) shares decreased by 13.4% to $8.22 during Wednesday's pre-market session. The company's market cap stands at $9.7 million.
• Community Health System (NYSE:CYH) stock decreased by 11.62% to $2.74. The market value of their outstanding shares is at $429.7 million. The company's, Q1 earnings came out yesterday.
• Clearmind Medicine (NASDAQ:CMND) shares fell 10.98% to $0.73. The company's market cap stands at $1.9 million.
• Edesa Biotech (NASDAQ:EDSA) shares decreased by 7.82% to $7.05. The company's market cap stands at $63.8 million.
• Basel Medical Group (NASDAQ:BMGL) shares fell 7.81% to $0.57. The market value of their outstanding shares is at $11.6 million.
• Autonomix Medical (NASDAQ:AMIX) shares fell 7.54% to $0.35. The market value of their outstanding shares is at $4.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.